Background
Anemia is a common clinical finding in HIV-infected patients and is associated with advanced disease, lower quality of life and higher mortality [
1‐
4]. Many factors may contribute to the development of anemia in HIV-infected patients including nutritional deficiencies, opportunistic infections, AIDS-related malignancies, drug treatment and a direct effect of HIV on the bone marrow [
4]. Iron deficiency and inflammation-induced iron maldistribution may also contribute to HIV-associated anemia [
5,
6]. Due to the effects of inflammation, iron is diverted from the circulation into the reticulo-endothelial system and other storage sites. Apart from inflammation, also HCV may possibly contribute to redistribution of iron [
7]. Hepcidin plays an important role in these processes [
8,
9], by limiting the availability of iron for hematopoiesis [
10]. Iron maldistribution may have another unwanted effect; it may increase susceptibility to opportunistic infections, and accelerate disease progression [
7,
11‐
14]. Indeed, iron overload is associated with a poor prognosis in HIV and Hepatitis C virus infections [
7].
Serum concentrations of ferritin and soluble transferrin receptor (sTfR) are frequently used to assess iron status [
15]. Low ferritin is an indicator of iron deficiency, but as ferritin is also an acute phase reactant its interpretation is difficult in the presence of inflammation. Levels of sTfR are predominantly determined by the erythropoietic activity. Iron deficiency leads to increased erythroblast numbers and increased TfR expression and thus to considerably elevated sTfR levels. In contrast, anemia of inflammation is characterized by normal sTfR levels [
6,
16].
So far, limited and sometimes contradictory reports have been published on ferritin and sTfR in HIV-infected patients. High plasma ferritin concentrations have been found among HIV-infected patients [
14,
17‐
19], while other studies have reported low ferritin concentrations [
20,
21]. Co-infection with hepatitis C virus (HCV) may further complicate the assessment of iron status, as HCV infection is associated with high plasma ferritin concentrations [
22]. With respect to sTfR levels in HIV patients, two studies found sTfR within the normal range [
14,
18], suggesting that sTfR is not affected by HIV infection [
12]. However, this is in contrast with two other studies showing an increase in sTfR concentrations after initiation of antiretroviral treatment (ART) [
19,
21].
In the present study, we examined the prevalence of anemia and its relation to mortality in a cohort of HIV patients in a setting where injecting drug use (IDU) is the main mode of HIV and HCV transmission [
23]. We also measured serum ferritin and sTfR, in relation to anemia, inflammation, stage of HIV disease, ART and HCV infection.
Discussion
The results from our study indicate that anemia is highly prevalent among HIV patients in Indonesia and that moderate to severe anemia is strongly related to mortality. This is in line with findings from other studies [
2,
3,
30‐
32]. We also report serum concentrations of ferritin and sTfR, both of which are often used for assessment of iron status. High serum ferritin concentrations were found, especially in patients with CD4 cell counts below 200 cells/mm
3. Iron redistribution in the setting of a prolonged acute phase response is most likely responsible for this observation and this may explain the reported iron excess in the liver, bone marrow and other organs during the advanced stages of HIV [
33]. Concentrations of CRP were however only moderately elevated and did not correlate well with ferritin concentrations. Although CRP is the most commonly used indicator of inflammation in daily practice, other acute phase response proteins such as a-1-acid-glycoprotein (AGP) may better reflect serum ferritin changes in inflammation because AGP remains elevated for a much longer time in sub-clinical chronic infections compared to CRP [
15,
34].
We found that sTfR concentrations were generally low and not related to CD4 count. This finding is in contrast to studies that showed that sTfR is not affected by HIV infection, even though these studies also report that sTfR alone has little value for differentiating anemia in the presence of inflammation [
12,
35,
36]. We hypothesize that low sTfR concentrations more likely reflects the presence of some degree of bone marrow suppression by HIV. Together, these findings suggest that both serum ferritin and sTfR concentrations may not be reliable indicators of iron status in advanced HIV infection.
The prevalence of anemia was more than 40% in our untreated HIV-infected patients, more or less similar to studies from outside Indonesia [
2,
18,
30,
37]. Severe anemia was noticed in nearly 5% of our patients and this was higher compared to previous data from Europe [
2] or Asia [
3] but lower compared to a study from Africa [
30]. Differences between the levels of immunodeficiency in the different studies may account for these differences. Our study also demonstrates that anemia is strongly related to increased mortality, as reported by others [
2,
3,
30,
31]. Interestingly, we found that this was also true after correction for CD4 cell count, indicating that anemia is an independent factor for HIV disease progression.
Measurement of iron parameters in a sub-group of patients revealed marked elevations in plasma ferritin, in line with earlier studies [
14,
17‐
19,
35]. Our study shows that high ferritin levels are strongly (and inversely) related to CD4 cell numbers but not to gender, HCV co-infection nor CRP as a marker of inflammation, as has been suggested by others [
19,
37]. Apart from the prolonged acute phase response, the inverse relation between ferritin and CD4 cell count may also be caused by increased oxidative stress [
38] related to depletion of CD4 cells [
39]. Furthermore, The HIV virus itself may increase ferritin levels as HIV-1 Nef protein directly down-regulates the hemochromatosis protein HFE and as such causes iron accumulation [
40]. However, the latter hypothesis was not supported by a study among HIV patients in Thailand, which reported no relation between serum ferritin concentrations and plasma HIV RNA [
20]. Finally, the role of inflammation cannot be completely excluded since inflammatory pathways that do not include IL-6 and CRP can lead to high ferritin concentrations [
41]. Interestingly, the inverse relation between ferritin levels and CD4 cell numbers disappeared after ART. This could be due to the effect of ART on oxidative stress, plasma HIV-RNA and/or inflammation. Our results argue against an important role of HCV as no relation was found between ferritin and HCV infection, although the number of subjects in whom all parameters were measured was limited.
Low ferritin levels (< 30 mg/ml) indicating iron deficiency were found in 6.3% of our patients and in 18.5% of the female patients. In previous studies from United States, iron deficiency anemia was found in 20% of HIV infected female injecting drug users [
42], and iron supplementation was found to reduce anemia without adverse effects on HCV co-infection or plasma HIV-RNA [
43]. However, iron supplementation should be done carefully and only in patients with iron deficiency as iron overload is associated with a poor prognosis of HIV-1 and hepatitis C virus infections and with growth of pathogenic microorganism [
7]. Indeed, excess mortality was reported among HIV-infected patients receiving low-dose oral iron with dapsone for
Pneumocystis carinii pneumonia prophylaxis [
11]. In our study, we did not find a significant relation between plasma ferritin level and mortality, even though those who died on average had two-fold higher plasma ferritin levels.
Unlike ferritin, sTfR levels showed no association with CD4 cell counts, neither among ART-naïve nor among ART-experienced patients. Furthermore, sTfR levels were not different in anemic versus non-anemic subjects. Our sTfR levels seem slightly low, especially in ART-naïve patients suggesting that reduced erythropoiesis may contribute to the development of anemia, although no relation was found between sTfR levels and the presence or degree of anemia. Plasma sTfR concentrations were not associated with mortality during follow-up. This was also found in other studies which showed an increase of sTfR following ART [
19,
21], and no relation between sTfR levels and disease progression [
19].
Our study has several limitations as it was observational, and as iron parameters were only measured in a subset of patients. Furthermore, no data are available on food or micronutrient intake which might affect iron status, and on occurrence of other opportunistic infections causing anemia. Tuberculosis could be important cause of anemia and could confound the results, although sensitivity analysis showed this was not the case. Furthermore we did not adjust ferritin concentrations for circulating HIV-RNA which are not measured routinely in ART-naïve patients. To be able to see the effects of ART on iron parameters, we excluded non-adherent patients. Loss to follow-up may have affected the estimated mortality, although we believe this did not affect our conclusions, since there was no significant difference in clinical characteristics including degree of anemia and CD4 cell count between patients with and without follow-up (data not shown).
Acknowledgements
We would like to thank Director of Hasan Sadikin General Hospital and Dean of the Medical Faculty Padjadjaran University for encouraging and accommodating research in their institutions.
This study was supported by 'IMPACT' (Integrated Management of Prevention And Care and Treatment of HIV/AIDS), a collaborative research and implementation program of Padjadjaran University, Bandung, Indonesia; Maastricht University and Radboud University Nijmegen, the Netherlands; and Antwerpen University, Belgium. IMPACT is funded by the European Commission (SANTE/2005/105-033)
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
RW designed, performed statistical analysis and prepared the manuscript. RS, ARI and AZ, did laboratory examinations and help collected data. HJ, QdM, RvC and AvdV designed, gave advice on statistical analysis and prepared the manuscript. All authors read and approved the final manuscript.